Medicinal Chemistry Research

, Volume 27, Issue 1, pp 153–160 | Cite as

A novel chromonyl thiohydantoin with anti-proliferative action on primary hepatocellular carcinoma cells

  • Cigdem Ozen
  • Meltem Ceylan-Unlusoy
  • Mehmet Ozturk
  • Oya Bozdag-DundarEmail author
Original Research


Chromone, imidazolidinedione, thiohydantoin and 2,4-thiazolidinedione structures are known to be cytotoxic to cancer cells. In this study, biological activities of previously synthesized 18 chromonyl-2,4-thiazolidinediones/imidazolidinediones/thiohydantoins were tested by sulforhodamine B assay in five liver and one breast cancer cell lines. It was shown that a hybrid chromonyl thiohydantoin derivative C9 was able to significantly suppress the proliferation of the liver cancer cell lines which are very resistant to anticancer drugs. According to 50% growth inhibition concentrations of C9, well differentiated hepatocellular carcinoma cell line Huh7 and breast adenocarcinoma cell line Mcf7 cells are found to be highly sensitive to C9 with IC50 values between 4.9–5.2 µM. Poorly differentiated human liver cancer cell line Snu449 is found to be the most resistant to C9. Further studies show that C9 causes morphological changes in Snu449 cells. However, it does not induce significant senescence response or cell cycle arrest. On the other hand, Huh7 cells are found to be arrested in G2/M phase of the cell cycle after 24 and 72 h treatment. In conclusion, a novel chromonyl thiohydantoin hybrid molecule effectively stops or slows down the proliferation of well-differentiated hepatocellular carcinoma cells that exist in primary tumors.


Antiproliferative Hepatocellular carcinoma Liver cancer Chromonyl-2,4-thiazolidinediones Imidazolidinedione Thiohydantoin 



This work was supported by Research Organization of Ankara University, Turkey (No: 09B3336003 and 12B3336003). One of the authors was supported by TUBA DSAP program. Biological part of the study was supported by the Scientific and Technological Research Council of Turkey with project 113S389.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. AbuHammad S, Zihlif M (2013) Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics 101(4):213–220CrossRefPubMedGoogle Scholar
  2. Abul Kashem Liton M, Salma U, Chandra Bhowmick A (2014) Cytotoxicity and 2D-QSAR study of some heterocyclic compounds. Arabian J Chem 7:639–646CrossRefGoogle Scholar
  3. Azizmohammadi M, Khoobi M, Ramazani A, Emami S, Zarrin A, Firuzi O, Miri R, Shafiee A (2013) 2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents. Eur J Med Chem 59:15–22CrossRefPubMedGoogle Scholar
  4. Bae MA, Rhee H, Song BJ (2003) Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 139(1):67–75CrossRefPubMedGoogle Scholar
  5. Ceylan-Unlusoy M, Verspohl EJ, Ertan R (2010) Synthesis and antidiabetic activity of some new chromonyl-2,4-thiazolidinediones. J Enzyme Inhib Med Chem 25(6):784–789CrossRefPubMedGoogle Scholar
  6. Ceylan-Unlusoy M, Kazak C, Bayro O, Verspohl EJ, Ertan R, Bozdag-Dundar O (2013) Synthesis and antidiabetic activity of 2,4-thiazolidinedione, imidazolidinedione and 2-thioxo-imidazolidine-4-one derivatives bearing 6-methyl chromonyl pharmacophore. J Enzyme Inhib Med Chem 28(6):1205–1210CrossRefGoogle Scholar
  7. Cragg GM, Grothaus PG, Newman DJ (2009) Impact of natural products on developing new anti-cancer agents. Chem Rev 109:3012–3043CrossRefPubMedGoogle Scholar
  8. De Luca P, De Siervi A (2016) Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis. Front Biosci (Elite Ed) 1(8):72–83Google Scholar
  9. Di Braccio M, Grossi G, Roma G, Marzano C, Baccichetti F, Simonato M, Bordin F (2003) Pyran derivatives: part XXI. Antiproliferative and cytotoxic properties of novel N-substituted 4-aminocoumarins, their benzo-fused derivatives, and some related 2-aminochromones. II Farmaco 58:1083–1097CrossRefGoogle Scholar
  10. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92(20):9363–9367CrossRefPubMedPubMedCentralGoogle Scholar
  11. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365(12):1118–1127CrossRefPubMedGoogle Scholar
  12. Forner A, Gilabert M, Bruix J, Raoul JL (2014) Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 11(9):525–535CrossRefPubMedGoogle Scholar
  13. Germano D, Daniele B (2014) Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol 20(12):3087–3099CrossRefPubMedPubMedCentralGoogle Scholar
  14. Germano D, Tinessa V, Barletta E, Cannella L, Daniele B (2013) Medical treatment of hepatocellular carcinoma. Minerva Med 104(5):545–561PubMedGoogle Scholar
  15. Keri RS, Budagumpi S, Pai RK, Balakrishna RG (2014) Chromones as a privileged scaffold in drug discovery: a review. Eur J Med Chem 78:340–374CrossRefPubMedGoogle Scholar
  16. Koga H, Harada M, Ohtsubo M, Shishido S, Kumemura H, Hanada S, Taniguchi E, Yamashita K, Kumashiro R, Ueno T, Sata M (2003) Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 37(5):1086–1096CrossRefPubMedGoogle Scholar
  17. Martens S, Mithofer A (2005) Flavones and flavone synthases. Phytochemistry 66:2399–2407CrossRefPubMedGoogle Scholar
  18. Middleton Jr E, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease and cancer. Pharmacol Rev 52:673–751PubMedGoogle Scholar
  19. Parveen M, Malla AM, Yaseen Z, Ali A, Alam M (2014) Synthesis, characterization, DNA-binding studies and acetylcholinesterase inhibition activity of new 3-formyl chromone derivatives. J Photochem Photobiol B 130:179–187CrossRefPubMedGoogle Scholar
  20. Rodier F, Campisi J (2011) Four faces of cellular senescence. J Cell Biol 192(4):547–556CrossRefPubMedPubMedCentralGoogle Scholar
  21. Shen Y-C, Hsu C, Chen J-Y, Cheng A-L (2004) Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines. Br J Cancer 91(8):1561–1565CrossRefPubMedPubMedCentralGoogle Scholar
  22. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM (2010) The global burden of cancer: priorities for prevention. Carcinogenesis 31(1):100–110CrossRefPubMedGoogle Scholar
  23. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112–1116CrossRefPubMedGoogle Scholar
  24. Villanueva A, Hernandez-Gea V, Llovet JM (2013) Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 10(1):34–42CrossRefPubMedGoogle Scholar
  25. Wörns MA, Galle PR (2010) Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 19(5):615–629CrossRefPubMedGoogle Scholar
  26. Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC, Atabey N, Ozturk M (2009) Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer 8:90CrossRefPubMedPubMedCentralGoogle Scholar
  27. Zhu AX (2012) Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol 39(4):493–502CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Cigdem Ozen
    • 1
  • Meltem Ceylan-Unlusoy
    • 2
  • Mehmet Ozturk
    • 1
  • Oya Bozdag-Dundar
    • 2
    Email author
  1. 1.Izmir International Biomedicine and Genome CenteriBG-Izmir, Dokuz Eylul UniversityBalcovaTurkey
  2. 2.Department of Pharmaceutical Chemistry, Faculty of PharmacyAnkara UniversityTandoganTurkey

Personalised recommendations